Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3057% below fair value
$0.51−0.02 (-3.73%)
Close on Nov 16, 2026Market cap $78.16MP/E –Yield –
Coherus Oncology total assets
Total assets on the balance sheet at the end of each period.
Coherus Oncology's total assets was $191.18M at Jun 30, 2026. For fiscal 2025 it was $258.34M, down 42.4% from the year before. Over ten years it grew 2.0% a year on average. The highest annual figure on record is $841.65M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.34M | -42.4% |
| FY2024 | Dec 31, 2024 | $448.53M | -28.8% |
| FY2023 | Dec 31, 2023 | $629.60M | +30.9% |
| FY2022 | Dec 31, 2022 | $480.85M | -29.2% |
| FY2021 | Dec 31, 2021 | $679.33M | -19.3% |
| FY2020 | Dec 31, 2020 | $841.65M | +105.8% |
| FY2019 | Dec 31, 2019 | $408.93M | +311.1% |
| FY2018 | Dec 31, 2018 | $99.47M | -38.8% |
| FY2017 | Dec 31, 2017 | $162.61M | -8.9% |
| FY2016 | Dec 31, 2016 | $178.49M | -16.0% |
| FY2015 | Dec 31, 2015 | $212.38M | +13.4% |
| FY2014 | Dec 31, 2014 | $187.22M | +294.6% |
| FY2013 | Dec 31, 2013 | $47.45M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $191.18M | -56.5% |
| Q1 FY2026 | Mar 31, 2026 | $266.02M | -28.3% |
| Q4 FY2025 | Dec 31, 2025 | $258.34M | -42.4% |
| Q3 FY2025 | Sep 30, 2025 | $516.52M | +2.3% |
| Q2 FY2025 | Jun 30, 2025 | $439.46M | -34.9% |
| Q1 FY2025 | Mar 31, 2025 | $371.07M | -51.4% |
| Q4 FY2024 | Dec 31, 2024 | $448.53M | -28.8% |
| Q3 FY2024 | Sep 30, 2024 | $505.00M | -13.5% |
| Q2 FY2024 | Jun 30, 2024 | $674.86M | +43.7% |
| Q1 FY2024 | Mar 31, 2024 | $763.55M | +89.7% |
| Q4 FY2023 | Dec 31, 2023 | $629.60M | +30.9% |
| Q3 FY2023 | Sep 30, 2023 | $583.78M | +6.0% |
| Q2 FY2023 | Jun 30, 2023 | $469.59M | -14.0% |
| Q1 FY2023 | Mar 31, 2023 | $402.43M | -32.2% |
| Q4 FY2022 | Dec 31, 2022 | $480.85M | -29.2% |
| Q3 FY2022 | Sep 30, 2022 | $550.91M | -25.7% |
| Q2 FY2022 | Jun 30, 2022 | $546.00M | -26.2% |
| Q1 FY2022 | Mar 31, 2022 | $593.39M | -14.4% |
| Q4 FY2021 | Dec 31, 2021 | $679.33M | -19.3% |
| Q3 FY2021 | Sep 30, 2021 | $741.73M | -7.7% |
| Q2 FY2021 | Jun 30, 2021 | $739.54M | -2.3% |
| Q1 FY2021 | Mar 31, 2021 | $693.30M | +48.6% |
| Q4 FY2020 | Dec 31, 2020 | $841.65M | +105.8% |
| Q3 FY2020 | Sep 30, 2020 | $803.73M | +145.5% |
| Q2 FY2020 | Jun 30, 2020 | $756.61M | +214.7% |
| Q1 FY2020 | Mar 31, 2020 | $466.54M | +150.7% |
| Q4 FY2019 | Dec 31, 2019 | $408.93M | +311.1% |
| Q3 FY2019 | Sep 30, 2019 | $327.38M | +131.4% |
| Q2 FY2019 | Jun 30, 2019 | $240.46M | +27.7% |
| Q1 FY2019 | Mar 31, 2019 | $186.12M | +44.9% |
| Q4 FY2018 | Dec 31, 2018 | $99.47M | -38.8% |
| Q3 FY2018 | Sep 30, 2018 | $141.46M | -25.5% |
| Q2 FY2018 | Jun 30, 2018 | $188.31M | +9.3% |
| Q1 FY2018 | Mar 31, 2018 | $128.46M | -43.5% |
| Q4 FY2017 | Dec 31, 2017 | $162.61M | -8.9% |
| Q3 FY2017 | Sep 30, 2017 | $189.76M | -1.4% |
| Q2 FY2017 | Jun 30, 2017 | $172.25M | – |
| Q1 FY2017 | Mar 31, 2017 | $227.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $178.49M | – |
| Q3 FY2016 | Sep 30, 2016 | $192.36M | – |
See a number that looks wrong?